Literature DB >> 23236069

Outer domain of HIV-1 gp120: antigenic optimization, structural malleability, and crystal structure with antibody VRC-PG04.

M Gordon Joyce1, Masaru Kanekiyo, Ling Xu, Christian Biertümpfel, Jeffrey C Boyington, Stephanie Moquin, Wei Shi, Xueling Wu, Yongping Yang, Zhi-Yong Yang, Baoshan Zhang, Anqi Zheng, Tongqing Zhou, Jiang Zhu, John R Mascola, Peter D Kwong, Gary J Nabel.   

Abstract

The outer domain of the HIV-1 gp120 envelope glycoprotein contains the epitope for broadly neutralizing antibodies directed to the CD4-binding site, many of which are able to neutralize over 90% of circulating HIV-1 isolates. While the outer domain is conformationally more stable than other portions of the HIV-1 envelope, efforts to express the outer domain as an immunogen for eliciting broadly neutralizing antibodies have not been successful, potentially because natural outer domain variants do not bind strongly to antibodies such as VRC01. In this study, we optimized the antigenic properties of the HIV-1 Env outer domain to generate OD4.2.2, from the KER2018 strain of clade A HIV-1, enabling it to bind antibodies such as VRC01 with nanomolar affinity. The crystal structure of OD4.2.2 in complex with VRC-PG04 was solved at 3.0-Å resolution and compared to known crystal structures including (i) the structure of core gp120 bound by VRC-PG04 and (ii) a circularly permutated version of the outer domain in complex with antibody PGT128. Much of the VRC-PG04 epitope was preserved in the OD4.2.2 structure, though with altered N and C termini conformations. Overall, roughly one-third of the outer domain structure appeared to be fixed in conformation, independent of alterations in termini, clade, or ligand, while other portions of the outer domain displayed substantial structural malleability. The crystal structure of OD4.2.2 with VRC-PG04 provides atomic-level details for an HIV-1 domain recognized by broadly neutralizing antibodies and insights relevant to the rational design of an immunogen that could elicit such antibodies by vaccination.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23236069      PMCID: PMC3571475          DOI: 10.1128/JVI.02717-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  41 in total

1.  Broad HIV-1 neutralization mediated by CD4-binding site antibodies.

Authors:  Yuxing Li; Stephen A Migueles; Brent Welcher; Krisha Svehla; Adhuna Phogat; Mark K Louder; Xueling Wu; George M Shaw; Mark Connors; Richard T Wyatt; John R Mascola
Journal:  Nat Med       Date:  2007-08-26       Impact factor: 53.440

2.  Immunodominance and antigenic variation of the principal neutralization domain of HIV-1.

Authors:  G Zwart; H Langedijk; L van der Hoek; J J de Jong; T F Wolfs; C Ramautarsing; M Bakker; A de Ronde; J Goudsmit
Journal:  Virology       Date:  1991-04       Impact factor: 3.616

3.  Antibody neutralization and escape by HIV-1.

Authors:  Xiping Wei; Julie M Decker; Shuyi Wang; Huxiong Hui; John C Kappes; Xiaoyun Wu; Jesus F Salazar-Gonzalez; Maria G Salazar; J Michael Kilby; Michael S Saag; Natalia L Komarova; Martin A Nowak; Beatrice H Hahn; Peter D Kwong; George M Shaw
Journal:  Nature       Date:  2003-03-20       Impact factor: 49.962

4.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

5.  Mechanism of human immunodeficiency virus type 1 resistance to monoclonal antibody B12 that effectively targets the site of CD4 attachment.

Authors:  Xueling Wu; Tongqing Zhou; Sijy O'Dell; Richard T Wyatt; Peter D Kwong; John R Mascola
Journal:  J Virol       Date:  2009-08-19       Impact factor: 5.103

6.  The development of CD4 binding site antibodies during HIV-1 infection.

Authors:  Rebecca M Lynch; Lillian Tran; Mark K Louder; Stephen D Schmidt; Myron Cohen; Rebecca Dersimonian; Zelda Euler; Elin S Gray; Salim Abdool Karim; Jennifer Kirchherr; David C Montefiori; Sengeziwe Sibeko; Kelly Soderberg; Georgia Tomaras; Zhi-Yong Yang; Gary J Nabel; Hanneke Schuitemaker; Lynn Morris; Barton F Haynes; John R Mascola
Journal:  J Virol       Date:  2012-05-09       Impact factor: 5.103

7.  Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120.

Authors:  J P Moore; Y Cao; L Qing; Q J Sattentau; J Pyati; R Koduri; J Robinson; C F Barbas; D R Burton; D D Ho
Journal:  J Virol       Date:  1995-01       Impact factor: 5.103

8.  Human anti-HIV-neutralizing antibodies frequently target a conserved epitope essential for viral fitness.

Authors:  John Pietzsch; Johannes F Scheid; Hugo Mouquet; Florian Klein; Michael S Seaman; Mila Jankovic; Davide Corti; Antonio Lanzavecchia; Michel C Nussenzweig
Journal:  J Exp Med       Date:  2010-08-02       Impact factor: 14.307

9.  MolProbity: all-atom structure validation for macromolecular crystallography.

Authors:  Vincent B Chen; W Bryan Arendall; Jeffrey J Headd; Daniel A Keedy; Robert M Immormino; Gary J Kapral; Laura W Murray; Jane S Richardson; David C Richardson
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2009-12-21

10.  Phaser crystallographic software.

Authors:  Airlie J McCoy; Ralf W Grosse-Kunstleve; Paul D Adams; Martyn D Winn; Laurent C Storoni; Randy J Read
Journal:  J Appl Crystallogr       Date:  2007-07-13       Impact factor: 3.304

View more
  24 in total

Review 1.  Computational tools for epitope vaccine design and evaluation.

Authors:  Linling He; Jiang Zhu
Journal:  Curr Opin Virol       Date:  2015-03-31       Impact factor: 7.090

Review 2.  Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning.

Authors:  Peter D Kwong; John R Mascola; Gary J Nabel
Journal:  Nat Rev Immunol       Date:  2013-09       Impact factor: 53.106

3.  Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer.

Authors:  Dmitry Lyumkis; Jean-Philippe Julien; Natalia de Val; Albert Cupo; Clinton S Potter; Per-Johan Klasse; Dennis R Burton; Rogier W Sanders; John P Moore; Bridget Carragher; Ian A Wilson; Andrew B Ward
Journal:  Science       Date:  2013-10-31       Impact factor: 47.728

Review 4.  Elicitation of HIV-1-neutralizing antibodies against the CD4-binding site.

Authors:  Ivelin S Georgiev; M Gordon Joyce; Tongqing Zhou; Peter D Kwong
Journal:  Curr Opin HIV AIDS       Date:  2013-09       Impact factor: 4.283

Review 5.  Advances in structure-based vaccine design.

Authors:  Daniel W Kulp; William R Schief
Journal:  Curr Opin Virol       Date:  2013-06-25       Impact factor: 7.090

6.  Flow cytometry reveals that H5N1 vaccination elicits cross-reactive stem-directed antibodies from multiple Ig heavy-chain lineages.

Authors:  James R R Whittle; Adam K Wheatley; Lan Wu; Daniel Lingwood; Masaru Kanekiyo; Steven S Ma; Sandeep R Narpala; Hadi M Yassine; Gregory M Frank; Jonathan W Yewdell; Julie E Ledgerwood; Chih-Jen Wei; Adrian B McDermott; Barney S Graham; Richard A Koup; Gary J Nabel
Journal:  J Virol       Date:  2014-02-05       Impact factor: 5.103

7.  Eliciting neutralizing antibodies with gp120 outer domain constructs based on M-group consensus sequence.

Authors:  Yali Qin; Marisa Banasik; SoonJeung Kim; Adam Penn-Nicholson; Habtom H Habte; Celia LaBranche; David C Montefiori; Chong Wang; Michael W Cho
Journal:  Virology       Date:  2014-08       Impact factor: 3.616

8.  Diverse recombinant HIV-1 Envs fail to activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447-52D.

Authors:  Andrew T McGuire; Jolene A Glenn; Adriana Lippy; Leonidas Stamatatos
Journal:  J Virol       Date:  2013-12-18       Impact factor: 5.103

9.  Epitope-focused immunogens against the CD4-binding site of HIV-1 envelope protein induce neutralizing antibodies against auto- and heterologous viruses.

Authors:  Hua Wang; Xiangjun Chen; Dianhong Wang; Chen Yao; Qian Wang; Jiayu Xie; Xuanling Shi; Ye Xiang; Wanli Liu; Linqi Zhang
Journal:  J Biol Chem       Date:  2017-11-29       Impact factor: 5.157

Review 10.  Strategies to guide the antibody affinity maturation process.

Authors:  Nicole A Doria-Rose; M Gordon Joyce
Journal:  Curr Opin Virol       Date:  2015-04-24       Impact factor: 7.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.